Skip to main content

Table 3 Drugs administered during the follow-up

From: Comparison of clinical features and outcomes between patients with early and delayed lupus nephritis

Variables Total (n = 171) Patients with early lupus nephritis (n = 106) Patients with delayed lupus nephritis (n = 65) p-value
Immunosuppressive agents
 Glucocorticoids 171 (100.0) 106 (100.0) 65 (100.0) 0.999
 Cumulative glucocorticoid dosage (mg)a 11,315.0 (5195.3–18,697.5) 10,889.6 (5145.0–17,306.3) 14,370.0 (5472.5–20,703.8) 0.181
 Cyclophosphamide 57 (33.3) 42 (39.6) 15 (23.1) 0.026
 Mycophenolate mofetil 133 (77.8) 83 (78.3) 50 (76.9) 0.834
 Tacrolimus 37 (21.6) 24 (22.6) 13 (20.0) 0.685
 Cyclosporine 8 (4.7) 6 (5.7) 2 (3.1) 0.711
 Azathioprine 24 (14.0) 13 (12.3) 11 (16.9) 0.396
 Hydroxychloroquine 98 (57.3) 55 (51.9) 43 (66.2) 0.051
  1. Values are expressed as median (interquartile range) or n (%)
  2. aCumulative glucocorticoid dosage was calculated in prednisolone equivalent dosage